Conditions: 0.25 mg · four weeks · early satiety.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
Why does this happen, and what would falsify the usual explanation?
four weeks at 0.25 mg is 28 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 0.25 mg back by 28 days. Whether that reduces early satiety depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 0.25 mg is 0.25 mg on day 1 and on day 28. A symptom driven by the rate of change has 28 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot early satiety against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|---|---|---|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
Mechanically, liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Hold rather than escalate while symptoms are active. Always.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
In practice, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
The top of the schedule is not the target. The working dose is.
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
The underlying point is that holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
Four half-lives between steps, minimum. Work it out for your agent.
edited 23 Sept 2024 by esther_vandeVelde — expanded the table to cover the lower concentration
Escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
The relevant detail is that this is the single most consequential controllable variable in the whole experience, and people routinely rush it.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.